To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Etravirine (TMC-125) is an drug currently under investigation for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to entravirine. Etravirine is being developed by Tibotec, a subsidiary of Johnson & Johnson. The Food and Drug Administration is scheduled to review the safety and efficacy data for etravirine in early 2008.
Additional recommended knowledge
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etravirine". A list of authors is available in Wikipedia.|